HeXell-2020
Phase 2Small molecule
HeXell-2020 is one of 49 small molecule programs targeting Mesenchymal Stem Cells. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
114 competitors in Coronary Artery Disease
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Brilinta
AstraZenecaApproved
Corlanor
AmgenApproved
Farxiga
AstraZenecaApproved
Niacor
AbbVieApproved
Ozempic
Novo NordiskApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Effient
CCosette Pharmaceuticals, Inc.
Approved
Glucophage
EMD SeronoApproved
Aggrastat
MMedicure
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Mesenchymal Stem Cells1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HeXell-2020. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHexun Biosciences Co., LTD.